Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

121P - Neoadjuvant sintilimab and anlotinib combined with chemotherapy for resectable NSCLC: A prospective, single arm, multicenter study


31 Mar 2023


Poster Display session


Xiaolong Yan


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


X. Yan1, H. Duan2, T. Wang3, Z. Luo3

Author affiliations

  • 1 Xi'an/CN
  • 2 The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, xi'an/CN
  • 3 The Third People's Hospital of Chongqing Medical University, Chong Qing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 121P


To explore the efficacy and safety of neoadjuvant Sintilimab and Anlotinib combined with chemotherapy for resectable NSCLC.


Before operation, the patients were treated with Sintilimab (200 mg) and Anlotinib (10 mg, po, day 1–14) combined with chemotherapy for 3 cycles, and surgery was performed 4 weeks after the last chemotherapy. After operation, patients were treated with Q3W of Sintilimab (200 mg) for 1 year. Primary end point: Complete pathological response (pCR). Secondary end point: Major pathological response (MPR), safety.


39 patents were included in the study group, including 35 males and 4 females; 30 people with smoking index > 400, 9 people with smoking index < 400; There were 9 cases of adenocarcinoma and 30 cases of squamous cell carcinoma. In addition, 4, 6, 12 and 17 patients in this group were in stages IIA, IIB, IIIA, and IIIB, respectively. Thirty-five patients finally received surgical treatment, one patient refused any treatment due to grade 3 liver damage, and three patients refused surgery after completing neoadjuvant treatment. The pCR of intention to treat (ITT) population is 21 (53.8%), the MPR is 25 (64.1%). The pCR of Per-protocol (PP) population is 60%, and the MPR is 71.4%. According to RECIST 1.1, there was 1 case of progress disease, 9 cases of SD, 27 cases of PR and 2 cases of CR in ITT population. The pCR and ORR of squamous cell carcinoma is much higher than those of adenocarcinoma in ITT or PP population. There were three patients with EGFR mutation (included Exon 19 and L858R) in adenocarcinoma. The incidence rate of AE events above grade 3 related to treatment was 20 (51.3%).

Table: 121P
Patient characteristics (N,%)
≥6024 (61.5)
<6015 (38.5)
Male35 (89.7)
Female4 (10.3)
Smoking Index
≥40030 (76.9)
<4009 (23.1)
Pathological type
Squamous cell carcinoma30 (76.9)
Adenocarcinoma9 (23.1)
Clinical stage
IIA4 (10.3)
IIB6 (15.4)
IIIA12 (30.8)
IIIB17 (43.5)
Pathological response
PCR(ITT)21 (53.8)
MPR(ITT)25 (64.1)
PCR(PP)21 (60.0)
MPR(PP)25 (71.4)
Squamous cell carcinoma (PCR-PP, N = 26)19(73.1)
Squamous cell carcinoma (MPR-PP, N = 26)23(88.5)
Adenocarcinoma (PCR-PP, N = 9)3 (33.3)
Adenocarcinoma (MPR-PP, N = 9)3 (33.3)
ORR(ITT)29 (74.4)
ORR(PP)25 (71.4)
Squamous cell carcinoma (ORR-PP, N = 26)21 (80.8)
Adenocarcinoma (ORR-PP, N = 9)5 (55.6)


The neoadjuvant treatment of Sintilimab and Anlotinib combined with chemotherapy can significantly increase the pCR of resectable NSCLC, which is an effective treatment method. However, the perioperative AE events should be paid attention to.

Clinical trial identification


Legal entity responsible for the study

The authors.


The National Natural Science Foundation of China (No. 81871866) Miaozi Talent Fund of Tangdu Hospital of Air Force Military Medical University.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.